Complement protection and anaphylatoxins in neuroinflammation
神经炎症中的补体保护和过敏毒素
基本信息
- 批准号:7911418
- 负责人:
- 金额:$ 4.83万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2007
- 资助国家:美国
- 起止时间:2007-09-03 至 2009-11-30
- 项目状态:已结题
- 来源:
- 关键词:Alzheimer&aposs DiseaseAmyotrophic Lateral SclerosisAnaphylatoxinsAntibodiesApoptosisAstrocytosisAutoimmune DiseasesBiological ModelsBiologyBrainBrain regionCell DeathCellular biologyCentral Nervous System DiseasesChelating AgentsComplementComplement 2Complement 3aComplement 5aComplement ActivationComplement component C1ComplexCopperCorpus CallosumCuprizoneDataDemyelinationsDietDiseaseEnvironmentEnzymesExcisionGeneticHumanHuntington DiseaseImmuneImmune systemIndividualInfiltrationInflammationInflammatory ResponseInvestigationLeadLymphocyteMediatingMediator of activation proteinModelingMultiple SclerosisMusMyelinNeuraxisNeurogliaNeuropathyOligodendrogliaPathologyPathway interactionsPatientsPharmaceutical PreparationsPick Disease of the BrainPlayProcessProductionProteinsRecombinantsResearchRoleSignal TransductionSpinal CordSystemTestingToxic effectbiological systemschemotherapy induced neuropathydesignfeedinggenetic regulatory proteinhuman diseasemouse crry proteinmouse modelnervous system disorderneuroinflammationnovelpreventreceptorresearch studytherapeutic target
项目摘要
Inflammation in the central nervous system is often accompanied by complement activation and the
complement system has been implicated in diverse disorders such as Alzheimer's disease, amyotrophic
lateral sclerosis and multiple sclerosis. We have utilized the cuprizone model of demyelination-remyelination
and here show that complement is a negative factor during demyelination, however lack of an intact
complement system significantly delays remyelination. In addition, there is decreased expression of the
protective Crry protein, suggesting increased susceptiblity to complement activation. In support of this idea,
CNS-specific soluble Crry protein completely inhibits demyelination. These results indicate that complement
is active even in CNS diseases without antibody involvement (as is the case in the cuprizone model). In
order to further delineate the role of complement in neuroinflammation we propose to test the following
hypotheses: (1) The production of anaphylatoxin proteins plays a key role in demyelination, yet are also
important for remyelination. Both C3a and C5a are produced during complement activation, yet it is very
difficult to dissect the roles of these proteins, either alone or in combination. We have generated novel
adenoviral constructs and we have mice with genetic deletions in the receptors for these proteins that we
can use to test our hypothesis. (2) Loss of Crry expression creates an environment in the corpus callosum
that facilitates complement activation. Our preliminary data have shown significant loss of Crry protein in
cuprizone-treated mice and CNS production of soluble Crry protein prevents demyelination. These data
show that primary demyelination can be prevented, but the effect on remyelination is yet unknown. We will
use adenovirally delivered soluble Crry protein to test the ability of the protein to alter local demyelination
and remyelination in this system. Our studies will begin to uncover how different complement proteins
interact in the CNS to mediate diverse effector functions. This information will be critical for understanding
how and when complement might be a candidate therapeutic target in CNS disease.
中枢神经系统中的炎症通常伴随补体激活,并且补体激活可导致中枢神经系统炎症。
补体系统与多种疾病有关,例如阿尔茨海默病、肌萎缩性侧索硬化症、
侧索硬化和多发性硬化。我们已经利用脱髓鞘-髓鞘再生的铜腙模型
在脱髓鞘过程中,补体是一个负性因素,然而缺乏完整的
补体系统显著延迟髓鞘再生。此外,在细胞凋亡中,
保护性Crry蛋白,表明对补体激活的易感性增加。为了支持这一想法,
CNS特异性可溶性Crry蛋白完全抑制脱髓鞘。这些结果表明,
即使在没有抗体参与的CNS疾病中也是有活性的(如在铜腙模型中的情况)。在
为了进一步阐明补体在神经炎症中的作用,我们建议测试以下内容
假设:(1)过敏毒素蛋白质的产生在脱髓鞘中起关键作用,但也
对髓鞘再生很重要C3 a和C5 a都是在补体激活过程中产生的,但它非常
很难剖析这些蛋白质的作用,无论是单独还是组合。我们创造了新的
腺病毒构建体,我们有这些蛋白质受体基因缺失的小鼠,
可以用来检验我们的假设(2)Crry表达的缺失在胼胝体中创造了一个环境,
促进补体激活我们的初步数据显示,在哺乳动物中,
cuprizone处理的小鼠和CNS产生可溶性Crry蛋白防止脱髓鞘。这些数据
表明原发性脱髓鞘可以预防,但对髓鞘再生的影响尚不清楚。我们将
使用腺病毒递送的可溶性Crry蛋白来测试该蛋白改变局部脱髓鞘的能力
和髓鞘再生。我们的研究将开始揭示不同的补体蛋白
在CNS中相互作用以介导不同的效应子功能。这些信息对于理解
补体如何以及何时成为CNS疾病候选治疗靶点。
项目成果
期刊论文数量(2)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
CNS-specific expression of C3a and C5a exacerbate demyelination severity in the cuprizone model.
- DOI:10.1016/j.molimm.2010.08.007
- 发表时间:2010-11
- 期刊:
- 影响因子:3.6
- 作者:Ingersoll SA;Martin CB;Barnum SR;Martin BK
- 通讯作者:Martin BK
c-Jun and c-Fos regulate the complement factor H promoter in murine astrocytes.
- DOI:10.1016/j.molimm.2011.08.013
- 发表时间:2011-10
- 期刊:
- 影响因子:3.6
- 作者:Fraczek LA;Martin CB;Martin BK
- 通讯作者:Martin BK
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
BRIAN K MARTIN其他文献
BRIAN K MARTIN的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('BRIAN K MARTIN', 18)}}的其他基金
Complement protection and anaphylatoxins in neuroinflammation
神经炎症中的补体保护和过敏毒素
- 批准号:
7670725 - 财政年份:2007
- 资助金额:
$ 4.83万 - 项目类别:
Complement protection and anaphylatoxins in neuroinflammation
神经炎症中的补体保护和过敏毒素
- 批准号:
7406829 - 财政年份:2007
- 资助金额:
$ 4.83万 - 项目类别:
TAXOL INDUCED GENE EXPRESSION IN BREAST CARCINOMA
紫杉醇诱导乳腺癌基因表达
- 批准号:
2111181 - 财政年份:1996
- 资助金额:
$ 4.83万 - 项目类别:
TAXOL INDUCED GENE EXPRESSION IN BREAST CARCINOMA
紫杉醇诱导乳腺癌基因表达
- 批准号:
2111180 - 财政年份:1995
- 资助金额:
$ 4.83万 - 项目类别:
相似国自然基金
新型F-18标记香豆素衍生物PET探针的研制及靶向Alzheimer's Disease 斑块显像研究
- 批准号:81000622
- 批准年份:2010
- 资助金额:20.0 万元
- 项目类别:青年科学基金项目
阿尔茨海默病(Alzheimer's disease,AD)动物模型构建的分子机理研究
- 批准号:31060293
- 批准年份:2010
- 资助金额:26.0 万元
- 项目类别:地区科学基金项目
跨膜转运蛋白21(TMP21)对引起阿尔茨海默病(Alzheimer'S Disease)的γ分泌酶的作用研究
- 批准号:30960334
- 批准年份:2009
- 资助金额:22.0 万元
- 项目类别:地区科学基金项目
相似海外基金
Pathophysiological mechanisms of hypoperfusion in mouse models of Alzheimer?s disease and small vessel disease
阿尔茨海默病和小血管疾病小鼠模型低灌注的病理生理机制
- 批准号:
10657993 - 财政年份:2023
- 资助金额:
$ 4.83万 - 项目类别:
Social Connectedness and Communication in Parents with Huntington''s Disease and their Offspring: Associations with Psychological and Disease Progression
患有亨廷顿病的父母及其后代的社会联系和沟通:与心理和疾病进展的关联
- 批准号:
10381163 - 财政年份:2022
- 资助金额:
$ 4.83万 - 项目类别:
The Role of Menopause-Driven DNA Damage and Epigenetic Dysregulation in Alzheimer s Disease
更年期驱动的 DNA 损伤和表观遗传失调在阿尔茨海默病中的作用
- 批准号:
10531959 - 财政年份:2022
- 资助金额:
$ 4.83万 - 项目类别:
The Role of Menopause-Driven DNA Damage and Epigenetic Dysregulation in Alzheimer s Disease
更年期驱动的 DNA 损伤和表观遗传失调在阿尔茨海默病中的作用
- 批准号:
10700991 - 财政年份:2022
- 资助金额:
$ 4.83万 - 项目类别:
Interneurons as early drivers of Huntington´s disease progression
中间神经元是亨廷顿病进展的早期驱动因素
- 批准号:
10518582 - 财政年份:2022
- 资助金额:
$ 4.83万 - 项目类别:
Interneurons as Early Drivers of Huntington´s Disease Progression
中间神经元是亨廷顿病进展的早期驱动因素
- 批准号:
10672973 - 财政年份:2022
- 资助金额:
$ 4.83万 - 项目类别:
Social Connectedness and Communication in Parents with Huntington''s Disease and their Offspring: Associations with Psychological and Disease Progression
患有亨廷顿病的父母及其后代的社会联系和沟通:与心理和疾病进展的关联
- 批准号:
10585925 - 财政年份:2022
- 资助金额:
$ 4.83万 - 项目类别:
Oligodendrocyte heterogeneity in Alzheimer' s disease
阿尔茨海默病中的少突胶质细胞异质性
- 批准号:
10180000 - 财政年份:2021
- 资助金额:
$ 4.83万 - 项目类别:
Serum proteome analysis of Alzheimer´s disease in a population-based longitudinal cohort study - the AGES Reykjavik study
基于人群的纵向队列研究中阿尔茨海默病的血清蛋白质组分析 - AGES 雷克雅未克研究
- 批准号:
10049426 - 财政年份:2021
- 资助金额:
$ 4.83万 - 项目类别:
Repurposing drugs for Alzheimer´s disease using a reverse translational approach
使用逆翻译方法重新利用治疗阿尔茨海默病的药物
- 批准号:
10295809 - 财政年份:2021
- 资助金额:
$ 4.83万 - 项目类别:














{{item.name}}会员




